The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined.
To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, dox...
Jing Chen, F. Guan, Zhi-Peng Cheng et al.· Frontiers in Immunology· 0 citations
Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...
Jia Xu, Lin Liu, Wei Xie et al.· Nature Medicine· 0 citations
In vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 and CD38 exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells.
Chaofan Wang, Wanting Wang, Mo-Ran Wang et al.· Cell Death & Disease· 0 citations
Findings highlight a previously underappreciated role of IL‐10 in shaping NK‐cell reconstitution post‐CAR‐T cell therapy, particularly in the setting of CRS, which may benefit patients with CRS accompanied by elevated IL‐10 levels.
Xin-Di Wang, W. Luo, Ying-Ying Li et al.· Clinical & Translational Imm...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.